IncobotulinumtoxinA (Xeomin) injection for lower and upper limb spasticity due to cerebral palsy

This page provides the factsheet for IncobotulinumtoxinA (Xeomin) injection for lower and upper limb spasticity due to cerebral palsy.

Page last updated: 23 February 2026

From 1 March 2026, MBS items 18354 and 18361 will be amended to allow providers to use IncobotulinumtoxinA (Xeomin) to treat lower- and upper-limb spasticity due to cerebral palsy. MBS item 18354 will be amended to remove the requirement for patients to be ambulant to receive treatment. These changes were recommended by the MSAC at the July 2025 meeting.

Further information is available in the factsheet below:

Word version - IncobotulinumtoxinA (Xeomin) injection for lower and upper limb spasticity due to cerebral palsy.DOCXWord version - IncobotulinumtoxinA (Xeomin) injection for lower and upper limb spasticity due to cerebral palsy.DOCX

PDF version - IncobotulinumtoxinA (Xeomin) injection for lower and upper limb spasticity due to cerebral palsy.pdfPDF version - IncobotulinumtoxinA (Xeomin) injection for lower and upper limb spasticity due to cerebral palsy.pdf

In this section